AMGN

Amgen Inc. (AMGN) | Rumor.io

Amgen

AMGN

Attention (50-day avg)0.01%

Attention rank (50-day avg)#420

Bullish sentiment (50-day avg)72%

Price to earnings ratio25.9

Market capitalization226.1B

Earnings per share16.1

Dividend yield (TTM)2.41%

Revenue (annual)36.8B

Net income (annual)7.7B

Social

What share of all stock conversation is about AMGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% +0	0.01% 0	0.01% -0.01

Sep 23

$AMGN rose 4.3% after a Phase 3 win in Sjögren's, but still hasn't undone a trial miss from earlier in the year.
The company's stock price has recovered some from a 9% drop two weeks ago, but is still 6.2% below its September 4 close.
Amgen has a settlement payout of $74 million, with eligible investors able to claim past losses and not necessarily needing to still hold the stock.

Generated by AI

Sentiment

Of the messages about AMGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	98.46% +2.57	68.6% -18.52	88.2% +2.4
Bearish	0% 0	1.54% -2.57	31.4% +18.52	11.8% -2.4

Bullish· Aug 5

Amgen reported a 4.5% increase in earnings per share, exceeding expectations and beating the forecast by 12%.
The company raised its full-year outlook, boosting adjusted earnings per share for fiscal year 2026 and increasing its sales forecast.
Amgen's stock price has reached a new all-time high, with a +6.17% increase on the day, and several analysts have raised their target prices for the company.

Bearish· Sep 8

Amgen's stock plummeted 10.1% on its worst day in 25 years, with investors questioning the viability of its competing treatment after Novartis' experimental cardiovascular drug failed in a Phase III trial.
A Phase III trial failure by Novartis' competing Lp(a) drug pelacarsen has raised doubts about Amgen's own Lp(a) candidate, olpasiran, which is still in development, leading to a 5.8% decline in Amgen's stock.
Amgen's stock price has been significantly impacted by the failure of Novartis' pelacarsen, with the biotech stock down 10% and dragging down the Dow Jones index, despite Amgen not being involved in the failed trial.

Generated by AI

Topics

Of the messages about AMGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	50%	40.11%	7.57%
Technical Analysis	100%	50%	16.34%	5.03%
Macro	0%	0%	21.49%	42.75%
Controversies	0%	0%	6.51%	0.56%
Analysts	0%	0%	14.74%	42.57%
Earnings	0%	0%	0.8%	1.51%

Earnings· Aug 4

Amgen's Q2 earnings beat estimates, with revenue of $10.1B exceeding estimates by $629M and a 10% YoY growth, and non-GAAP EPS of $6.29 beating estimates by $0.67.
The company raised its full-year revenue guidance to $38.2B-$39.4B, exceeding estimates, and also increased its full-year adjusted EPS guidance to $22.30-$23.50, outpacing estimates.
Amgen's six key growth drivers grew 26% YoY, generating nearly 70% of Q2 product sales, and the company's free cash flow increased to $3.5B, a 84% YoY increase.

Analysts· Feb 1

Amgen's (AMGN) price target was lowered by multiple analysts, with Credit Suisse cutting it to $220, Barclays to $230, BMO to $253, and Oppenheimer to $294.
Analysts' confidence in AMGN is mixed, with a buy consensus of 68% among 33 analysts, indicating mildly positive sentiment.
Analysts from RBC Capital, Oppenheimer, Cowen, Wells Fargo, and Credit Suisse lowered their price targets for AMGN, with RBC maintaining a Sector Perform rating.

Announcements· Mar 14

Amgen Inc. (AMGN) may see a shift in prescribing patterns as awareness of new guidelines grows, potentially leading to increased use of Nexlizet in place of PCSK9 inhibitors like Repatha.
The addition of Amgen's drugs to the TrumpRx platform may trigger a sector rotation and create opportunities in options trading, although the move is seen as playing political chess for tariff relief and insulation rather than addressing broad drug pricing issues.
Amgen's inclusion in the TrumpRx platform introduces regulatory and political risk, and market participants are advised to monitor for volatility.

Controversies· Sep 1

Amgen ($AMGN) has settled a lawsuit with the FTC over its $27.8 billion acquisition of Horizon Therapeutics ($HZNP), allowing the deal to move forward.
As part of the settlement, Amgen is prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products.
The deal was initially blocked by the FTC, but Amgen and Horizon Therapeutics have now resolved the lawsuit, clearing the way for the acquisition to close.

Macro· Apr 25

Amgen (AMGN) is mentioned as a potential alternative investment due to its strong performance.
The company's stock is highlighted as a possible option for investors seeking to diversify their portfolios.
Amgen's stock price is noted as a significant factor in investment decisions, with its performance being compared to that of the SCHD ETF.

Technical Analysis· Nov 26

$AMGN was down due to a 52-week study on their weight loss drug, but the author thinks the stock was down too much.
The author believes $AMGN is topping out and expects a drop to 227-207, with 255 being a key level to hold.
The author is bullish on $AMGN, citing bullish RSI divergence at support and thinks the stock will gap down to the $250s.

Generated by AI

Community

Of the messages about AMGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	17.98%	28.77%	50.43%	38.22%
Newcomers	82.02%	71.23%	49.57%	61.78%

Regulars· Sep 22

Amgen's investigational therapy, dazodalibep, met its primary endpoint in a Phase 3 study for patients with moderate-to-severe systemic Sjögren's disease.
The positive topline results for dazodalibep led to a 3.5% increase in Amgen's shares and a 4% jump in shares premarket.
The successful Phase 3 trial data for dazodalibep could strengthen Amgen's pipeline story and support momentum beyond its existing drug portfolio.

Newcomers· Sep 9

Newcomers to the AMGN discussion are focused on the impact of Novartis' Phase 3 pelacarsen failure on the cardiovascular biotech space and the resulting reassessment of Amgen's Lp(a) setback.
The concern among newcomers is that the market is now questioning the viability of Amgen's Lp(a) drug due to the failure of a competitor's similar drug, leading to a 10% drop in Amgen's stock.
Newcomers are also focused on Amgen's recent Q2 blowout beat and its AI drug pipeline momentum, which some see as a major dip-buying opportunity after a recent sector-wide sympathy selloff.

Generated by AI

News

Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

22h agoYahoo Finance

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on Amgen. While Citi noted that the results […]

1d agoYahoo Finance

Amgen (AMGN), What Is Behind The Fresh Attention?

Amgen (AMGN) just reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, an update that puts fresh attention on the stock's autoimmune pipeline potential. Set against that clinical update, Amgen’s share price has climbed 15.5% over the past 90 days and 27.6% year to date, while the 1-year total shareholder return of 56.9% and 5-year total shareholder return of 131.0% point to strong longer term momentum building around the story. Spot emerging...

1d agoYahoo Finance

Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus

Microsoft, Bloom Energy and Amgen highlight Zacks' latest market moves, with strong gains across Focus List, recommendation and dividend portfolios.

1d agoYahoo Finance

Why Amgen’s Pipeline Just Got More Interesting

Amgen Inc. (NASDAQ:AMGN)’s experimental drug dazodalibep met the main goal of a late-stage trial for Sjögren’s disease. After 48 weeks, patients with moderate-to-severe disease activity showed statistically significant and clinically meaningful improvements. Most adverse events were mild to moderate, and only a small number of patients stopped treatment. Sjögren’s affects about 1% of the global […]

2d agoYahoo Finance

Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back

Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to Mesirow, a financial services firm based in Chicago. Amgen is not leaving. It has signed a long-term lease to stay on the roughly 660,000-square-foot campus, where it occupies one of the three buildings. The […]

2d agoYahoo Finance

Also Discussed

Investors talking about AMGN also mention

#	Name	Attention
1	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
2	Novartis AG Sponsored ADRNVS	0%-0.01
3	Sanofi ADRSNY	0%-0.01
4	Gilead Sciences, Inc.GILD	0%-0.04
5	Bristol-Myers Squibb CompanyBMY	0.01%0
6	Biogen IncBIIB	0%-0.01
7	Merck & Co., Inc.MRK	0.01%-0.06
8	Vertex Pharmaceuticals Incorporated Common StockVRTX	0%-0.01
9	AbbVie Inc.ABBV	0.03%-0.03
10	Johnson & JohnsonJNJ	0%-0.06

Amgen Inc.

Healthcare
Drug Manufacturers - General

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics. Its current portfolio focuses on serious diseases across oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases, with medicines delivered through biologics such as recombinant proteins and monoclonal antibodies. Amgen works with healthcare providers, hospitals, pharmacies, and wholesalers, serving patients in developed markets worldwide. The company’s role in the financial market is closely tied to its branded biologic medicines and research-driven product pipeline, which support its position as one of the leading independent biotechnology companies. Headquartered in Thousand Oaks, California, Amgen combines large-scale manufacturing and global distribution with a strong emphasis on innovative treatments for conditions with high unmet medical need.

Website

Location

One Amgen Center Drive

Thousand Oaks, CA, 91320-1799

United States

Social

What share of all stock conversation is about AMGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% +0	0.01% 0	0.01% -0.01

Sep 23

$AMGN rose 4.3% after a Phase 3 win in Sjögren's, but still hasn't undone a trial miss from earlier in the year.
The company's stock price has recovered some from a 9% drop two weeks ago, but is still 6.2% below its September 4 close.
Amgen has a settlement payout of $74 million, with eligible investors able to claim past losses and not necessarily needing to still hold the stock.

Generated by AI

Sentiment

Of the messages about AMGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	98.46% +2.57	68.6% -18.52	88.2% +2.4
Bearish	0% 0	1.54% -2.57	31.4% +18.52	11.8% -2.4

Bullish· Aug 5

Amgen reported a 4.5% increase in earnings per share, exceeding expectations and beating the forecast by 12%.
The company raised its full-year outlook, boosting adjusted earnings per share for fiscal year 2026 and increasing its sales forecast.
Amgen's stock price has reached a new all-time high, with a +6.17% increase on the day, and several analysts have raised their target prices for the company.

Bearish· Sep 8

Amgen's stock plummeted 10.1% on its worst day in 25 years, with investors questioning the viability of its competing treatment after Novartis' experimental cardiovascular drug failed in a Phase III trial.
A Phase III trial failure by Novartis' competing Lp(a) drug pelacarsen has raised doubts about Amgen's own Lp(a) candidate, olpasiran, which is still in development, leading to a 5.8% decline in Amgen's stock.
Amgen's stock price has been significantly impacted by the failure of Novartis' pelacarsen, with the biotech stock down 10% and dragging down the Dow Jones index, despite Amgen not being involved in the failed trial.

Generated by AI

Topics

Of the messages about AMGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	50%	40.11%	7.57%
Technical Analysis	100%	50%	16.34%	5.03%
Macro	0%	0%	21.49%	42.75%
Controversies	0%	0%	6.51%	0.56%
Analysts	0%	0%	14.74%	42.57%
Earnings	0%	0%	0.8%	1.51%

Earnings· Aug 4

Amgen's Q2 earnings beat estimates, with revenue of $10.1B exceeding estimates by $629M and a 10% YoY growth, and non-GAAP EPS of $6.29 beating estimates by $0.67.
The company raised its full-year revenue guidance to $38.2B-$39.4B, exceeding estimates, and also increased its full-year adjusted EPS guidance to $22.30-$23.50, outpacing estimates.
Amgen's six key growth drivers grew 26% YoY, generating nearly 70% of Q2 product sales, and the company's free cash flow increased to $3.5B, a 84% YoY increase.

Analysts· Feb 1

Amgen's (AMGN) price target was lowered by multiple analysts, with Credit Suisse cutting it to $220, Barclays to $230, BMO to $253, and Oppenheimer to $294.
Analysts' confidence in AMGN is mixed, with a buy consensus of 68% among 33 analysts, indicating mildly positive sentiment.
Analysts from RBC Capital, Oppenheimer, Cowen, Wells Fargo, and Credit Suisse lowered their price targets for AMGN, with RBC maintaining a Sector Perform rating.

Announcements· Mar 14

Amgen Inc. (AMGN) may see a shift in prescribing patterns as awareness of new guidelines grows, potentially leading to increased use of Nexlizet in place of PCSK9 inhibitors like Repatha.
The addition of Amgen's drugs to the TrumpRx platform may trigger a sector rotation and create opportunities in options trading, although the move is seen as playing political chess for tariff relief and insulation rather than addressing broad drug pricing issues.
Amgen's inclusion in the TrumpRx platform introduces regulatory and political risk, and market participants are advised to monitor for volatility.

Controversies· Sep 1

Amgen ($AMGN) has settled a lawsuit with the FTC over its $27.8 billion acquisition of Horizon Therapeutics ($HZNP), allowing the deal to move forward.
As part of the settlement, Amgen is prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products.
The deal was initially blocked by the FTC, but Amgen and Horizon Therapeutics have now resolved the lawsuit, clearing the way for the acquisition to close.

Macro· Apr 25

Amgen (AMGN) is mentioned as a potential alternative investment due to its strong performance.
The company's stock is highlighted as a possible option for investors seeking to diversify their portfolios.
Amgen's stock price is noted as a significant factor in investment decisions, with its performance being compared to that of the SCHD ETF.

Technical Analysis· Nov 26

$AMGN was down due to a 52-week study on their weight loss drug, but the author thinks the stock was down too much.
The author believes $AMGN is topping out and expects a drop to 227-207, with 255 being a key level to hold.
The author is bullish on $AMGN, citing bullish RSI divergence at support and thinks the stock will gap down to the $250s.

Generated by AI

Community

Of the messages about AMGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	17.98%	28.77%	50.43%	38.22%
Newcomers	82.02%	71.23%	49.57%	61.78%

Regulars· Sep 22

Amgen's investigational therapy, dazodalibep, met its primary endpoint in a Phase 3 study for patients with moderate-to-severe systemic Sjögren's disease.
The positive topline results for dazodalibep led to a 3.5% increase in Amgen's shares and a 4% jump in shares premarket.
The successful Phase 3 trial data for dazodalibep could strengthen Amgen's pipeline story and support momentum beyond its existing drug portfolio.

Newcomers· Sep 9

Newcomers to the AMGN discussion are focused on the impact of Novartis' Phase 3 pelacarsen failure on the cardiovascular biotech space and the resulting reassessment of Amgen's Lp(a) setback.
The concern among newcomers is that the market is now questioning the viability of Amgen's Lp(a) drug due to the failure of a competitor's similar drug, leading to a 10% drop in Amgen's stock.
Newcomers are also focused on Amgen's recent Q2 blowout beat and its AI drug pipeline momentum, which some see as a major dip-buying opportunity after a recent sector-wide sympathy selloff.

Generated by AI

Amgen

Social

Sep 23

Bullish· Aug 5

Bearish· Sep 8

Earnings· Aug 4

Analysts· Feb 1

Announcements· Mar 14

Controversies· Sep 1

Macro· Apr 25

Technical Analysis· Nov 26

Regulars· Sep 22

Newcomers· Sep 9

Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

Amgen (AMGN), What Is Behind The Fresh Attention?

Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus

Why Amgen’s Pipeline Just Got More Interesting

Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back

Also Discussed

Amgen Inc.

Company Information

Location

Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

Amgen (AMGN), What Is Behind The Fresh Attention?

Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus

Why Amgen’s Pipeline Just Got More Interesting

Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back

Also Discussed

Social

Sep 23

Bullish· Aug 5

Bearish· Sep 8

Earnings· Aug 4

Analysts· Feb 1

Announcements· Mar 14

Controversies· Sep 1

Macro· Apr 25

Technical Analysis· Nov 26

Regulars· Sep 22

Newcomers· Sep 9